Delhi-based biotech startup Cellogen Therapeutics has received regulatory approval for its Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cell therapy, marking a significant milestone in India's advancement in cell and gene therapy. This breakthrough introduces a novel treatment option for blood cancers, strengthening India’s position in global immunotherapy research.

India ranks third globally in cancer incidence and second in cancer-related deaths, with blood cancers accounting for 8% of new cases annually. Conditions such as leukemia, lymphoma, and multiple myeloma impact thousands of patients, including 30,000 children each year.

Unlike conventional CAR T cell therapies that target a single antigen, Cellogen’s bi-specific approach engages two tumor-specific antigens simultaneously, enhancing precision while reducing side effects like cytokine release syndrome and neurotoxicity.

Dr. Gaurav Kharya, founder of Cellogen, emphasized the three years of research behind this innovation, aiming to make world-class therapies more affordable and accessible. The technology is expected to reduce treatment costs by over 90%, supporting India’s Atmanirbhar Bharat initiative.

With $2 million in funding from NATCO Pharma and clinical trials planned in collaboration with CMC Vellore, Cellogen is working alongside regulatory bodies and research institutions to accelerate the availability of this life-saving treatment.